Raymond James Financial Inc. Purchases New Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Raymond James Financial Inc. purchased a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 131,505 shares of the company's stock, valued at approximately $746,000. Raymond James Financial Inc. owned 0.24% of Voyager Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Rhumbline Advisers grew its stake in shares of Voyager Therapeutics by 3.4% during the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock worth $405,000 after purchasing an additional 2,354 shares during the period. Empowered Funds LLC grew its stake in shares of Voyager Therapeutics by 5.3% during the 4th quarter. Empowered Funds LLC now owns 47,206 shares of the company's stock worth $268,000 after purchasing an additional 2,397 shares during the period. Wells Fargo & Company MN grew its stake in shares of Voyager Therapeutics by 3.7% during the 4th quarter. Wells Fargo & Company MN now owns 66,718 shares of the company's stock worth $378,000 after purchasing an additional 2,400 shares during the period. Picton Mahoney Asset Management grew its stake in shares of Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock worth $33,000 after purchasing an additional 2,444 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Voyager Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company's stock valued at $6,149,000 after buying an additional 4,729 shares in the last quarter. 48.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on VYGR. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the company an "overweight" rating in a research report on Wednesday, March 12th. Wedbush restated an "outperform" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group dropped their price target on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, March 13th. Finally, HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $13.97.

Insiders Place Their Bets

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the sale, the chief executive officer now directly owns 430,931 shares of the company's stock, valued at approximately $1,478,093.33. This trade represents a 2.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.39% of the stock is owned by corporate insiders.

Voyager Therapeutics Price Performance

NASDAQ:VYGR traded up $0.16 during mid-day trading on Monday, reaching $3.33. The company's stock had a trading volume of 70,033 shares, compared to its average volume of 444,396. The company's fifty day simple moving average is $3.52 and its two-hundred day simple moving average is $4.91. Voyager Therapeutics, Inc. has a twelve month low of $2.75 and a twelve month high of $9.55. The stock has a market cap of $184.14 million, a P/E ratio of 4.70 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million. Sell-side analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.